查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1347531

溃疡性结肠炎市场：2023-2028 年全球行业趋势、份额、规模、增长、机会和预测

Ulcerative Colitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3个工作天内

价格

市场概况：

2022年，全球溃疡性结肠炎市场规模达到74亿美元。展望未来，IMARC集团预计到2028年市场规模将达到102亿美元，2023-2028年復合年增长率（CAGR）为5.4%。

溃疡性结肠炎 (UC) 是一种慢性炎症性肠病 (IBD)，会引起消化道刺激、炎症和溃疡（疮）。它通常影响大肠（或结肠）和直肠的内壁。这些症状通常会随着时间的推移而出现，被诊断为 UC 的个体可能会经历轻微症状或无症状的时期。然而，它有时会导致衰弱或危及生命的并发症。虽然 UC 尚无法治愈，但治疗可以帮助患者控制和减轻症状、预防病情发作并实现长期缓解。因此，UC 治疗在全球范围内迅速受到关注，因为它有助于提高生活质量并确保患者的身心健康。

溃疡性结肠炎市场趋势：

UC 疾病的广泛流行和对可用治疗方案的认识不断提高是推动市场增长的主要因素。除此之外，强大的管道产品的存在和众多药物的不断进步正在增加产品需求。此外，各国政府正在采取多项倡议来提高人们对这种疾病的认识，并提高适当医疗设施的可及性和可用性。这与开发新疗法的研发（R＆D）活动的投资不断增加相结合，正在推动市场增长。此外，领先企业正致力于推出创新和更有效的药物，以扩大其产品组合併在市场上获得竞争优势。其他因素，包括生物仿製药的容易获得、医疗基础设施的改善、有利的报销政策以及消费者在医疗保健方面的支出增加，也创造了积极的市场前景。

本报告回答的关键问题：

  • 迄今为止，全球溃疡性结肠炎市场表现如何，未来几年将如何表现？
  • COVID-19 对全球溃疡性结肠炎市场有何影响？
  • 主要区域市场有哪些？
  • 根据类型划分市场是怎样的？
  • 根据疾病类型的市场划分是怎样的？
  • 根据分子类型的市场细分是什么？
  • 根据药物类型分類的市场是怎样的？
  • 根据给药途径，市场的分化是什么？
  • 基于分销渠道的市场细分是什么？
  • 行业价值链的各个阶段是什么？
  • 该行业的关键驱动因素和挑战是什么？
  • 全球溃疡性结肠炎市场的结构如何？谁是主要参与者？
  • 行业竞争程度如何？

目录

第一章：前言

第 2 章：范围和方法

  • 研究目的
  • 利益相关者
  • 数据源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球溃疡性结肠炎市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：按类型分類的市场细分

  • 轻度UC
    • 市场走向
    • 市场预测
  • 中度UC
    • 市场走向
    • 市场预测
  • 严重溃疡性结肠炎
    • 市场走向
    • 市场预测

第 7 章：按疾病类型分類的市场

  • 溃疡性直肠炎
    • 市场走向
    • 市场预测
  • 直肠乙状结肠炎
    • 市场走向
    • 市场预测
  • 左侧结肠炎
    • 市场走向
    • 市场预测
  • 全结肠炎或普遍性结肠炎
    • 市场走向
    • 市场预测
  • 暴发性结肠炎
    • 市场走向
    • 市场预测

第 8 章：按分子类型分類的市场

  • 小分子
    • 市场走向
    • 市场预测
  • 生物製剂
    • 市场走向
    • 市场预测

第 9 章：按药物类型分類的市场细分

  • 抗炎药
    • 市场走向
    • 市场预测
  • 抗肿瘤坏死因子生物製剂
    • 市场走向
    • 市场预测
  • 免疫抑製剂
    • 市场走向
    • 市场预测
  • 钙调磷酸酶抑製剂
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 10 章：按管理途径分類的市场

  • 口服
    • 市场走向
    • 市场预测
  • 可注射
    • 市场走向
    • 市场预测

第 11 章：按分销渠道分類的市场细分

  • 医院药房
    • 市场走向
    • 市场预测
  • 零售药店
    • 市场走向
    • 市场预测
  • 药店
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 12 章：按地区分類的市场细分

  • 北美
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳大利亚
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉美
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 按国家/地区分類的市场细分
    • 市场预测

第 13 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 14 章：价值链分析

第 15 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 16 章：价格分析

第17章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • AbbVie Inc.
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112023A5663

Market Overview:

The global ulcerative colitis market size reached US$ 7.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 10.2 Billion by 2028, exhibiting a growth rate (CAGR) of 5.4% during 2023-2028.

Ulcerative colitis (UC) refers to a chronic inflammatory bowel disease (IBD) that causes irritation, inflammation, and ulcers (sores) in the digestive tract. It typically affects the inner lining of the large intestine (or colon) and rectum. The symptoms generally develop over time, and individuals diagnosed with UC may experience periods of mild or no symptoms. However, it can sometimes lead to debilitating or life-threatening complications. While there is no cure for UC yet, the treatment can help patients manage and reduce their symptoms, prevent flare-ups, and bring about long-term remission. As a result, UC treatment is rapidly gaining traction across the globe as it can help enhance the quality of life and ensure the physical and mental wellbeing of the patients.

Ulcerative Colitis Market Trends:

The widespread prevalence of UC disease and the rising awareness regarding the available treatment options represent the primary factors driving the market growth. Besides this, the presence of strong pipeline products and continuous advancements in numerous drugs are augmenting the product demand. Additionally, governments of various countries are taking several initiatives to spread awareness about the condition and enhance the accessibility and availability of proper healthcare facilities. This, in confluence with the increasing investments in the research and development (R&D) activities for the development of novel therapies, is propelling the market growth. Furthermore, the leading players are focusing on launching innovative and more effective drugs to expand their product portfolio and gain a competitive edge in the market. Other factors, including the easy availability of biosimilar drugs, improving healthcare infrastructure, favorable reimbursement policies, and increasing consumer spending on healthcare, are also creating a positive market outlook.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global ulcerative colitis market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, disease type, molecule type, drug type, route of administration and distribution channel.

Breakup by Type:

Mild UC

Moderate UC

Severe UC

Breakup by Disease Type:

Ulcerative Proctitis

Proctosigmoiditis

Left-sided Colitis

Pancolitis or Universal Colitis

Fulminant Colitis

Breakup by Molecule Type:

Small Molecules

Biologics

Breakup by Drug Type:

Anti-Inflammatory Drugs

Anti-TNF Biologics

Immunosuppressant

Calcineurin Inhibitors

Others

Breakup by Route of Administration:

Oral

Injectable

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Drug Store

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

  • How has the global ulcerative colitis market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global ulcerative colitis market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the disease type?
  • What is the breakup of the market based on the molecule type?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global ulcerative colitis market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Ulcerative Colitis Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Mild UC
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Moderate UC
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Severe UC
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Ulcerative Proctitis
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Proctosigmoiditis
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Left-sided Colitis
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Pancolitis or Universal Colitis
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Fulminant Colitis
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Molecule Type

  • 8.1 Small Molecules
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Biologics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Drug Type

  • 9.1 Anti-Inflammatory Drugs
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Anti-TNF Biologics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Immunosuppressant
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Calcineurin Inhibitors
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Route of Administration

  • 10.1 Oral
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Injectable
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast

11 Market Breakup by Distribution Channel

  • 11.1 Hospital Pharmacies
    • 11.1.1 Market Trends
    • 11.1.2 Market Forecast
  • 11.2 Retail Pharmacies
    • 11.2.1 Market Trends
    • 11.2.2 Market Forecast
  • 11.3 Drug Store
    • 11.3.1 Market Trends
    • 11.3.2 Market Forecast
  • 11.4 Others
    • 11.4.1 Market Trends
    • 11.4.2 Market Forecast

12 Market Breakup by Region

  • 12.1 North America
    • 12.1.1 United States
      • 12.1.1.1 Market Trends
      • 12.1.1.2 Market Forecast
    • 12.1.2 Canada
      • 12.1.2.1 Market Trends
      • 12.1.2.2 Market Forecast
  • 12.2 Asia-Pacific
    • 12.2.1 China
      • 12.2.1.1 Market Trends
      • 12.2.1.2 Market Forecast
    • 12.2.2 Japan
      • 12.2.2.1 Market Trends
      • 12.2.2.2 Market Forecast
    • 12.2.3 India
      • 12.2.3.1 Market Trends
      • 12.2.3.2 Market Forecast
    • 12.2.4 South Korea
      • 12.2.4.1 Market Trends
      • 12.2.4.2 Market Forecast
    • 12.2.5 Australia
      • 12.2.5.1 Market Trends
      • 12.2.5.2 Market Forecast
    • 12.2.6 Indonesia
      • 12.2.6.1 Market Trends
      • 12.2.6.2 Market Forecast
    • 12.2.7 Others
      • 12.2.7.1 Market Trends
      • 12.2.7.2 Market Forecast
  • 12.3 Europe
    • 12.3.1 Germany
      • 12.3.1.1 Market Trends
      • 12.3.1.2 Market Forecast
    • 12.3.2 France
      • 12.3.2.1 Market Trends
      • 12.3.2.2 Market Forecast
    • 12.3.3 United Kingdom
      • 12.3.3.1 Market Trends
      • 12.3.3.2 Market Forecast
    • 12.3.4 Italy
      • 12.3.4.1 Market Trends
      • 12.3.4.2 Market Forecast
    • 12.3.5 Spain
      • 12.3.5.1 Market Trends
      • 12.3.5.2 Market Forecast
    • 12.3.6 Russia
      • 12.3.6.1 Market Trends
      • 12.3.6.2 Market Forecast
    • 12.3.7 Others
      • 12.3.7.1 Market Trends
      • 12.3.7.2 Market Forecast
  • 12.4 Latin America
    • 12.4.1 Brazil
      • 12.4.1.1 Market Trends
      • 12.4.1.2 Market Forecast
    • 12.4.2 Mexico
      • 12.4.2.1 Market Trends
      • 12.4.2.2 Market Forecast
    • 12.4.3 Others
      • 12.4.3.1 Market Trends
      • 12.4.3.2 Market Forecast
  • 12.5 Middle East and Africa
    • 12.5.1 Market Trends
    • 12.5.2 Market Breakup by Country
    • 12.5.3 Market Forecast

13 SWOT Analysis

  • 13.1 Overview
  • 13.2 Strengths
  • 13.3 Weaknesses
  • 13.4 Opportunities
  • 13.5 Threats

14 Value Chain Analysis

15 Porters Five Forces Analysis

  • 15.1 Overview
  • 15.2 Bargaining Power of Buyers
  • 15.3 Bargaining Power of Suppliers
  • 15.4 Degree of Competition
  • 15.5 Threat of New Entrants
  • 15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

  • 17.1 Market Structure
  • 17.2 Key Players
  • 17.3 Profiles of Key Players
    • 17.3.1 Abbott Laboratories
      • 17.3.1.1 Company Overview
      • 17.3.1.2 Product Portfolio
      • 17.3.1.3 Financials
      • 17.3.1.4 SWOT Analysis
    • 17.3.2 AbbVie Inc.
      • 17.3.2.1 Company Overview
      • 17.3.2.2 Product Portfolio
      • 17.3.2.3 Financials
      • 17.3.2.4 SWOT Analysis
    • 17.3.3 AstraZeneca plc
      • 17.3.3.1 Company Overview
      • 17.3.3.2 Product Portfolio
      • 17.3.3.3 Financials
      • 17.3.3.4 SWOT Analysis
    • 17.3.4 Bristol-Myers Squibb Company
      • 17.3.4.1 Company Overview
      • 17.3.4.2 Product Portfolio
      • 17.3.4.3 Financials
      • 17.3.4.4 SWOT Analysis
    • 17.3.5 Eli Lilly and Company
      • 17.3.5.1 Company Overview
      • 17.3.5.2 Product Portfolio
      • 17.3.5.3 Financials
      • 17.3.5.4 SWOT Analysis
    • 17.3.6 F. Hoffmann-La Roche Ltd.
      • 17.3.6.1 Company Overview
      • 17.3.6.2 Product Portfolio
      • 17.3.6.3 Financials
    • 17.3.7 GlaxoSmithKline plc
      • 17.3.7.1 Company Overview
      • 17.3.7.2 Product Portfolio
      • 17.3.7.3 Financials
      • 17.3.7.4 SWOT Analysis
    • 17.3.8 Johnson & Johnson
      • 17.3.8.1 Company Overview
      • 17.3.8.2 Product Portfolio
      • 17.3.8.3 Financials
      • 17.3.8.4 SWOT Analysis
    • 17.3.9 Merck & Co. Inc.
      • 17.3.9.1 Company Overview
      • 17.3.9.2 Product Portfolio
      • 17.3.9.3 Financials
      • 17.3.9.4 SWOT Analysis
    • 17.3.10 Pfizer Inc.
      • 17.3.10.1 Company Overview
      • 17.3.10.2 Product Portfolio
      • 17.3.10.3 Financials
      • 17.3.10.4 SWOT Analysis
    • 17.3.11 Takeda Pharmaceutical Company Limited
      • 17.3.11.1 Company Overview
      • 17.3.11.2 Product Portfolio
      • 17.3.11.3 Financials
      • 17.3.11.4 SWOT Analysis
    • 17.3.12 Teva Pharmaceutical Industries Ltd.
      • 17.3.12.1 Company Overview
      • 17.3.12.2 Product Portfolio
      • 17.3.12.3 Financials
      • 17.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Ulcerative Colitis Market: Major Drivers and Challenges
  • Figure 2: Global: Ulcerative Colitis Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Ulcerative Colitis Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Ulcerative Colitis Market: Breakup by Type (in %), 2022
  • Figure 5: Global: Ulcerative Colitis Market: Breakup by Disease Type (in %), 2022
  • Figure 6: Global: Ulcerative Colitis Market: Breakup by Molecule Type (in %), 2022
  • Figure 7: Global: Ulcerative Colitis Market: Breakup by Drug Type (in %), 2022
  • Figure 8: Global: Ulcerative Colitis Market: Breakup by Route of Administration (in %), 2022
  • Figure 9: Global: Ulcerative Colitis Market: Breakup by Distribution Channel (in %), 2022
  • Figure 10: Global: Ulcerative Colitis Market: Breakup by Region (in %), 2022
  • Figure 11: Global: Ulcerative Colitis (Mild UC) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Ulcerative Colitis (Mild UC) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Ulcerative Colitis (Moderate UC) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Ulcerative Colitis (Moderate UC) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Ulcerative Colitis (Severe UC) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Ulcerative Colitis (Severe UC) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Ulcerative Colitis (Ulcerative Proctitis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Ulcerative Colitis (Ulcerative Proctitis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: Ulcerative Colitis (Proctosigmoiditis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: Ulcerative Colitis (Proctosigmoiditis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: Ulcerative Colitis (Left-sided Colitis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: Ulcerative Colitis (Left-sided Colitis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: Global: Ulcerative Colitis (Pancolitis or Universal Colitis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: Global: Ulcerative Colitis (Pancolitis or Universal Colitis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: Global: Ulcerative Colitis (Fulminant Colitis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: Global: Ulcerative Colitis (Fulminant Colitis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: Global: Ulcerative Colitis (Small Molecules) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: Global: Ulcerative Colitis (Small Molecules) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: Global: Ulcerative Colitis (Biologics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: Global: Ulcerative Colitis (Biologics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: Global: Ulcerative Colitis (Anti-Inflammatory Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: Global: Ulcerative Colitis (Anti-Inflammatory Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: Global: Ulcerative Colitis (Anti-TNF Biologics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: Global: Ulcerative Colitis (Anti-TNF Biologics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: Global: Ulcerative Colitis (Immunosuppressant) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: Global: Ulcerative Colitis (Immunosuppressant) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: Global: Ulcerative Colitis (Calcineurin Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: Global: Ulcerative Colitis (Calcineurin Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: Global: Ulcerative Colitis (Other Drug Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: Global: Ulcerative Colitis (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: Global: Ulcerative Colitis (Oral) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: Global: Ulcerative Colitis (Oral) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: Global: Ulcerative Colitis (Injectable) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: Global: Ulcerative Colitis (Injectable) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: Global: Ulcerative Colitis (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: Global: Ulcerative Colitis (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: Global: Ulcerative Colitis (Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: Global: Ulcerative Colitis (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: Global: Ulcerative Colitis (Drug Store) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: Global: Ulcerative Colitis (Drug Store) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: Global: Ulcerative Colitis (Other Distribution Channels) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: Global: Ulcerative Colitis (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: North America: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: North America: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: United States: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: United States: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: Canada: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: Canada: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: Asia-Pacific: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: Asia-Pacific: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: China: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: China: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Japan: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: Japan: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: India: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: India: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: South Korea: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: South Korea: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: Australia: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: Australia: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Indonesia: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 72: Indonesia: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 73: Others: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 74: Others: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 75: Europe: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 76: Europe: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 77: Germany: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 78: Germany: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 79: France: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 80: France: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 81: United Kingdom: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 82: United Kingdom: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 83: Italy: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 84: Italy: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 85: Spain: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 86: Spain: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 87: Russia: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 88: Russia: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 89: Others: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 90: Others: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 91: Latin America: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 92: Latin America: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 93: Brazil: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 94: Brazil: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 95: Mexico: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 96: Mexico: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 97: Others: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 98: Others: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 99: Middle East and Africa: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 100: Middle East and Africa: Ulcerative Colitis Market: Breakup by Country (in %), 2022
  • Figure 101: Middle East and Africa: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 102: Global: Ulcerative Colitis Industry: SWOT Analysis
  • Figure 103: Global: Ulcerative Colitis Industry: Value Chain Analysis
  • Figure 104: Global: Ulcerative Colitis Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Ulcerative Colitis Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Ulcerative Colitis Market Forecast: Breakup by Type (in Million US$), 2023-2028
  • Table 3: Global: Ulcerative Colitis Market Forecast: Breakup by Disease Type (in Million US$), 2023-2028
  • Table 4: Global: Ulcerative Colitis Market Forecast: Breakup by Molecule Type (in Million US$), 2023-2028
  • Table 5: Global: Ulcerative Colitis Market Forecast: Breakup by Drug Type (in Million US$), 2023-2028
  • Table 6: Global: Ulcerative Colitis Market Forecast: Breakup by Route of Administration (in Million US$), 2023-2028
  • Table 7: Global: Ulcerative Colitis Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 8: Global: Ulcerative Colitis Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 9: Global: Ulcerative Colitis Market: Competitive Structure
  • Table 10: Global: Ulcerative Colitis Market: Key Players